ArticleBiological trace element research2026
Short-Chain Fatty Acids Mitigate Perinatal Methylmercury-Induced Cognitive Impairment Via Modulation of the Gut Microbiota Composition.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Methylmercury (MeHg) is a potent neurotoxin that disrupts neurodevelopment in offspring when exposure occurs early in life. However, to date, there is a lack of effective therapeutic strategies for MeHg toxicity. Short-chain fatty acids (SCFAs), metabolites of gut microbial fermentation, influence the gut-brain axis and offer neuroprotective effects. This study investigated the effects of a SCFA intervention on offspring cognitive impairment and gut microbiota dysbiosis following maternal MeHg exposure. The Morris water maze protocol was employed to evaluate cognitive performance in the filial generation of rats. SCFAs were quantified with gas chromatography, while microbial community profiling of the intestine was performed with high-throughput sequencing of the 16 S ribosomal RNA gene. Additionally, histopathological alterations were evaluated via hematoxylin and eosin (HE) staining. The results showed that SCFA supplementation significantly increased mercury excretion through the feces and reduced mercury accumulation in the colon and brain compared to the MeHg group. MeHg exposure markedly decreased colonic levels of acetate, propionate, and butyrate, but SCFA supplementation effectively restored these levels. Further investigations demonstrated that SCFA supplementation influenced the intestinal microbial community and restored its diversity, while HE staining revealed that SCFAs alleviated pathological damage to both the colon and brain tissues. Additionally, behavioral assessments demonstrated that MeHg exposure reduced platform crossings in offspring rats, while SCFA supplementation significantly enhanced cognitive performance. These findings highlight the potential of SCFAs in mitigating MeHg-induced damage and improving cognitive function, offering new insights into therapeutic approaches for neurotoxin exposure.
Indexed as
Identifiers
41639514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.